Cite

HARVARD Citation

    Theurey, P. et al. (2022). Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity. Endocrinology, diabetes & metabolism. 5 (6), p. n/a. [Online]. 
  
Back to record